Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.17.3.2 (
xanthine oxidase
)
8,383
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The mechanism(s) regulating nitric oxide synthase-1 (NOS1) localization within the cardiac myocyte in health and disease remains unknown. Here we tested the hypothesis that the PDZ-binding domain interaction between
CAPON
(carboxy-terminal PDZ ligand of NOS1), a NOS1 adaptor protein and NOS1, contribute to NOS1 localization in specific organelles within cardiomyocytes. Ventricular cardiomyocytes and whole heart homogenates were isolated from sham and post-myocardial infarction (MI) wild-type (C57BL/6) and NOS1(-/-) female mice for quantification of
CAPON
protein expression levels. NOS1,
CAPON
,
xanthine oxidoreductase
and Dexras1, a
CAPON
binding partner, were all present and enriched in isolated cardiac sarcoplasmic reticulum (SR) fractions.
CAPON
co-immunoprecipitated with the mu and alpha isoforms of NOS1 in whole heart lysates, and co-localization of
CAPON
and NOS1 was demonstrated in the SR and mitochondria with dual immuno-gold electron microscopy. Following MI,
CAPON
and NOS1 both redistributed to caveolae and colocalized with caveolin-3. In addition, following MI, expression level of
CAPON
remained unchanged and Dexras1 was reduced,
CAPON
binding to
xanthine oxidoreductase
was augmented and the plasma membrane calcium ATPase (PMCA) increased. In NOS1 deficient myocytes,
CAPON
abundance in the SR was reduced, and redistribution to caveolae and PMCA binding after MI was absent. Together these findings support the hypothesis that NOS1 redistribution in injured myocardium requires the formation of a complex with the PDZ adaptor protein
CAPON
.
...
PMID:Cardiac nitric oxide synthase-1 localization within the cardiomyocyte is accompanied by the adaptor protein, CAPON. 1980 18